
Further information on publisher’s website:
https://doi.org/10.1186/s13063-016-1768-4

Publisher’s copyright statement:
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Additional information:
Background
Aortic valve replacement is one of the most common cardiac surgical procedures performed worldwide. Conventional aortic valve replacement surgery is performed via a median sternotomy; the sternum is divided completely from the sternal notch to the xiphisternum. Minimally invasive aortic valve replacement, using a new technique called manubrium-limited ministernotomy, divides only the manubrium from the sternal notch to 1cm below the manubrio-sternal junction.

Over one third of patients undergoing conventional sternotomy develop clinically significant bleeding requiring post-operative red blood cell transfusions. Case series data suggest a potentially clinically significant difference in red blood cell transfusion requirements between the two techniques. Given the implications for NHS resources and patient outcomes, a definitive trial is needed.

Design
This is a single centre, single blind, randomised controlled trial, comparing aortic valve replacement surgery using manubrium-limited ministernotomy (intervention) and conventional median sternotomy (usual care). Two hundred and sixty patients will be randomised in a 1:1 ratio between the intervention and control arms, stratified by baseline logistic EuroSCORE and haemoglobin value. Patients will be followed for 12 weeks from discharge following their index operation. The primary outcome is the proportion of patients who receive a red blood cell transfusion post-operatively within 7 days of surgery. Secondary outcomes include red blood cell and blood product transfusions, blood loss, re-operation rates, sternal wound pain, quality of life, markers of inflammatory response, hospital discharge, health care utilisation, cost and cost effectiveness, and adverse events.

Discussion
This is the first trial to examine aortic valve replacement via manubrium-limited ministernotomy versus conventional sternotomy when comparing red blood cell transfusion rates following surgery. Surgical trials present significant challenges; strengths of this trial include a rigorous research design, standardised surgery performed by experienced consultant cardiothoracic surgeons, an agreed anaesthetic regimen, patient blinding, and consultant-led patient recruitment. The MAVRIC trial will demonstrate that complex surgical trials can be delivered to exemplary standards and provide the community with the knowledge required to inform future care for patients requiring aortic valve replacement surgery.
<table>
<thead>
<tr>
<th>Corresponding Author Secondary Information:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Corresponding Author's Institution:</td>
<td>UNIVERSITY OF DURHAM</td>
</tr>
<tr>
<td>Corresponding Author's Secondary Institution:</td>
<td></td>
</tr>
<tr>
<td>First Author:</td>
<td>Enoch Akowuah, MD</td>
</tr>
<tr>
<td>First Author Secondary Information:</td>
<td></td>
</tr>
<tr>
<td>Order of Authors:</td>
<td>Enoch Akowuah, MD</td>
</tr>
<tr>
<td></td>
<td>Andrew T Goodwin, PhD</td>
</tr>
<tr>
<td></td>
<td>W Andrew Owens, MD</td>
</tr>
<tr>
<td></td>
<td>Helen C Hancock, PhD</td>
</tr>
<tr>
<td></td>
<td>Rebecca Maier, MSc</td>
</tr>
<tr>
<td></td>
<td>Adetayo Kasim, PhD</td>
</tr>
<tr>
<td></td>
<td>Adrian Mellor, MD</td>
</tr>
<tr>
<td></td>
<td>Khalid Khan, MD</td>
</tr>
<tr>
<td></td>
<td>Gavin Murphy, MD</td>
</tr>
<tr>
<td></td>
<td>James M Mason, DPhil</td>
</tr>
<tr>
<td>Order of Authors Secondary Information:</td>
<td></td>
</tr>
<tr>
<td>Response to Reviewers:</td>
<td>Tianjing Li, Senior Editor, Trials</td>
</tr>
<tr>
<td></td>
<td>Dear Tianjing Li,</td>
</tr>
<tr>
<td></td>
<td>Re TRLS-D-16-00260 Manubrium-limited ministernotomy versus conventional sternotomy for aortic valve replacement: randomised controlled trial protocol (MAVRIC) Enoch Akowuah, MD; Andrew T Goodwin, PhD; W Andrew Owens, MD; Helen C Hancock, PhD; Rebecca Maier, MSc; Adetayo Kasim, PhD; Adrian Mellor, MD; Khalid Khan, MD; Gavin Murphy, MD; James M Mason, DPhil Trials</td>
</tr>
<tr>
<td></td>
<td>Many thanks for your recent correspondence regarding our paper. The research team has answered each of your comments in turn as well as those of the reviewer.</td>
</tr>
<tr>
<td></td>
<td>We have reviewed guidance regarding preparation of the paper alongside recently published protocols and hope the format is acceptable.</td>
</tr>
<tr>
<td></td>
<td>If anything below or in the paper is unclear, please do not hesitate to let us know.</td>
</tr>
<tr>
<td></td>
<td>Sincerely,</td>
</tr>
<tr>
<td></td>
<td>Helen Hancock (on behalf of the MAVRIC trial team)</td>
</tr>
<tr>
<td>Response to Reviewers:</td>
<td>Editor's comments:</td>
</tr>
<tr>
<td></td>
<td>1. Please specify your primary and secondary outcomes fully following the 5 elements as described in paper Zarin NEJM 2011364:852-60.</td>
</tr>
<tr>
<td></td>
<td>We have amended these in the paper, using tracked changes. In doing so we have reviewed the paper (above) as well as protocols recently published in Trials.</td>
</tr>
<tr>
<td></td>
<td>2. Please address the reviewer's comments.</td>
</tr>
</tbody>
</table>
We can confirm that we have reviewed and addressed the single reviewers comments; these are addressed in the paper, using tracked changes, and detailed below.

3. Did you upload a SPIRIT checklist?

We can confirm that a SPIRIT checklist has now been included

Reviewer #1:

The author proposed a randomized controlled trial to compare the outcome of aortic valve replacement surgery using manubrium-limited ministernotomy (intervention) and conventional median sternotomy (usual care). The result from the trial is important given that the surgery is commonly performed. However, the author was not very clear in the primary and secondary outcomes, and need to provide more information regarding the two procedures in the background. Additionally, the author should adopt more appropriate statistical models for analyzing the data. Some more specific comments:

1. It's not very clear to me if the manubrium-limited ministernotomy is comparable to conventional median sternotomy in serving the purpose of aortic valve replacement. For example, is the success rate of the two procedures similar? What about survival? Is there specific indications in patients that make one procedure more preferable? What's the advantage and disadvantage of both procedures? The author can introduce more about it in the background.

The trial compares two surgical approaches to gaining access to the heart for the purpose of aortic valve replacement surgery. The trial is not studying AVR per se. The two approaches in the trial are: manubrium-limited ministernotomy (intervention) and conventional median sternotomy (usual care); both are commonly performed in the NHS and are known to be successful and safe. The main aim of the trial is to ascertain any impact of the surgical approach on the need for red blood cell transfusion in the post-operative period. The trial is funded by the NIHR.

2. Is there criteria for modifying the allocated interventions for a given participant (eg, worsening of disease)?

No. These patients require a single surgical intervention to replace their aortic valve. Inclusion criteria state that all patients should be eligible for both surgical approaches. Recruitment timelines mean that the disease state is unlikely to worsen following confirmation of eligibility and date of surgery.

3. The primary and secondary outcomes are confusing and sometimes switched. For example, in page 15, the proportion of patients who receive a red blood cell transfusion was listed as both primary and secondary outcome. Need to be more specific and clear.

We have added details to the paper as requested, including timelines for data capture.

4. For the sample size, can you justify how you come up with 17% reduction? It seems to be a very optimistic estimation of the intervention effect.

An audit of 110 patients conducted in advance of designing the trial indicated 30% of patients receiving conventional AVR surgery required a red blood cell transfusion compared with 13% of patients undergoing manubrium-limited ministernotomy. It is on this that the reduction of 17% is based.

5. Analysis of the primary endpoint should be done more systematically and not only using Fisher's exact test. Since the proportion of people receiving blood transfusion is high, poisson regression or prevalence ratio derived from logistic regression is more appropriate. Although it's a randomized controlled trial, adjusting for potential confounders is still necessary.

We do not consider it appropriate to use Poisson regression or prevalence ratio to
analyse the binary endpoint given that the primary endpoint is whether a patient received a blood transfusion or not. Poisson regression might be more appropriate had the primary endpoint been count data, for example, the number of times each patient received a blood transfusion. We plan to adjust for potential confounders and stratification variables in a logistic regression model as a sensitivity analysis for the primary endpoint. This has been made explicit in the protocol.

6. Add statement of who will have access to the final trial data and disclosure of contractual agreements that limit such access to investigators

The main contract is the standard used across all NIHR projects; this contains standard clauses relating to data confidentiality, data protection and rights to data. All members of the research team, including investigators and trial statisticians, will have access to the trial data.

7. Provide informed consent materials as appendices. We have noted that this is not a specific requirement of the journal, and that other published protocols do not include this. If journal editors would like to discuss it's inclusion we would be happy to consider this request.

8. Abstract background. "Aortic valve replacement is one on the most" should be "one of the"

Thank you, we have made the alteration in the paper.
Title: Manubrium-limited ministernotomy versus conventional sternotomy for aortic valve replacement: randomised controlled trial protocol (MAVRIC)

1. Mr Enoch Akowuah
Cardiothoracic Division
The James Cook University Hospital
South Tees Hospitals NHS Foundation Trust
Marton Road
Middlesbrough
enoch.akowuah@nhs.net

2. Mr Andrew T Goodwin
Cardiothoracic Division
The James Cook University Hospital
South Tees Hospitals NHS Foundation Trust
Marton Road
Middlesbrough
andrew.goodwin1@nhs.net

3. Mr W Andrew Owens
Cardiothoracic Division
The James Cook University Hospital
South Tees Hospitals NHS Foundation Trust
Marton Road
Middlesbrough
andrew.owens@stees.nhs.uk
4. Dr Helen C Hancock

Durham Clinical Trials Unit
School of Medicine, Pharmacy and Health
Durham University, Queen's Campus,
University Boulevard
Thornaby
Stockton-on-Tees
TS17 6BH
helen.h Hancock@durham.ac.uk

5. Mrs Rebecca Maier

Durham Clinical Trials Unit
School of Medicine, Pharmacy and Health
Durham University, Queen's Campus,
University Boulevard
Thornaby
Stockton-on-Tees
TS17 6BH
rebecca.maier@durham.ac.uk

6. Dr Adetayo Kasim

Durham Clinical Trials Unit
School of Medicine, Pharmacy and Health
Durham University, Queen's Campus,
University Boulevard
Thornaby
Stockton-on-Tees
TS17 6BH

a.s.kasim@durham.ac.uk

7. Dr Adrian Mellor
Cardiothoracic Division
The James Cook University Hospital
South Tees Hospitals NHS Foundation Trust
Marton Road
Middlesbrough
adrian.mellor@stees.nhs.uk

8. Dr Khalid Khan
Cardiothoracic Division
The James Cook University Hospital
South Tees Hospitals NHS Foundation Trust
Marton Road
Middlesbrough
khalid.khan@stees.nhs.uk

9. Professor Gavin Murphy
Department of Cardiovascular Sciences
University of Leicester
Clinical Sciences Wing
Glenfield General Hospital
Leicester
LE3 9QP
gjm19@leicester.ac.uk
10. Professor James Mason

Professor of Health Economics

Warwick Medical School, University of Warwick

Coventry, CV4 7AL, United Kingdom

J.Mason@warwick.ac.uk
Abstract

Background
Aortic valve replacement is one of the most common cardiac surgical procedures performed worldwide. Conventional aortic valve replacement surgery is performed via a median sternotomy; the sternum is divided completely from the sternal notch to the xiphisternum. Minimally invasive aortic valve replacement, using a new technique called manubrium-limited ministernotomy, divides only the manubrium from the sternal notch to 1cm below the manubrio-sternal junction.

Over one third of patients undergoing conventional sternotomy develop clinically significant bleeding requiring post-operative red blood cell transfusions. Case series data suggest a potentially clinically significant difference in red blood cell transfusion requirements between the two techniques. Given the implications for NHS resources and patient outcomes, a definitive trial is needed.

Methods/Design
This is a single centre, single blind, randomised controlled trial, comparing aortic valve replacement surgery using manubrium-limited ministernotomy (intervention) and conventional median sternotomy (usual care). Two hundred and seventy patients will be randomised in a 1:1 ratio between the intervention and control arms, stratified by baseline logistic EuroSCORE and haemoglobin value. Patients will be followed for 12 weeks from discharge following their index operation. The primary outcome is the proportion of patients who receive a red blood cell transfusion post-operatively within 7 days of surgery. Secondary outcomes include red blood cell and blood product transfusions, blood loss, re-operation rates, sternal wound pain, quality of life, markers of inflammatory response, hospital discharge, health care utilisation, cost and cost effectiveness, and adverse events.
Discussion

This is the first trial to examine aortic valve replacement via manubrium-limited ministernotomy versus conventional sternotomy when comparing red blood cell transfusion rates following surgery. Surgical trials present significant challenges; strengths of this trial include a rigorous research design, standardised surgery performed by experienced consultant cardiothoracic surgeons, an agreed anaesthetic regimen, patient blinding, and consultant-led patient recruitment. The MAVRIC trial will demonstrate that complex surgical trials can be delivered to exemplary standards and provide the community with the knowledge required to inform future care for patients requiring aortic valve replacement surgery.

Trial Registration

International Standard Randomized Controlled Trial Number (ISRCTN)

ISRCTN29567910, registered on 3 February 2014.

Keywords

Aortic Valve Replacement (AVR); Manubrium-limited ministernotomy; Minimally invasive aortic valve replacement; Sternotomy; Red Blood Cell transfusion; Inflammatory Response
Background and Rationale

Aortic Valve Replacement (AVR)

AVR is one of the most common cardiac surgical procedures performed worldwide (1, 2). Patients suffer symptoms of chest pain, shortness of breath and dizziness as a result of aortic stenosis or regurgitation. Nearly 10,000 patients undergo AVR surgery in the United Kingdom every year (2). Patient outcomes of AVR performed in the UK from 2004 to 2009 were recently published (3) showing a 26% increase in the number of patients undergoing this surgery during this period. At The James Cook University Hospital (JCUH) in the North of England, an audit over the same time period confirmed a 24% increase in the number of AVR operations. It is anticipated that the number of AVR operations will continue to increase.

Blood Transfusion Following AVR

There is significant morbidity associated with AVR surgery. Consequently, blood loss and the subsequent requirement for transfusion of red blood cells (RBCs) and blood products are key indicators of quality. Over one third of patients undergoing conventional sternotomy develop clinically significant bleeding and require a post-operative RBC transfusion (4,5). Blood transfusion can have adverse clinical effects including post-operative lung injury, organ dysfunction, confusion, and immunosuppression (6); complications of transfusion have been directly linked to prolonged hospital stay and increased mortality after cardiac surgery (5, 7-12). Additionally, there is a small risk of transmitting viral infection from blood donor to recipient (13). Currently cardiac surgical procedures use 6% of all donor blood available in the UK (14). An analysis of patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National database indicated that of 41,227 patients who underwent AVR surgery 2,342 (6%) required a second operation due to excessive bleeding (3).
Retrospective studies have shown that blood loss and transfusion requirements are significantly less with minimally invasive AVR (15-17); however, most reported using a 4th space ministernotomy incision rather than manubrium-limited approach. No study thus far has tested red blood cell transfusion requirements in a randomised controlled trial using manubrium-limited ministernotomy.

Rationale for cChoice of cComparators

Surgical tTechniques in AVR

Usual Care: Conventional Sternotomy:

Conventional surgery for AVR is performed via a median sternotomy, in which the sternum is divided completely from the sternal notch to the xiphisternum. The operation includes cardiopulmonary bypass established by siting cannulas in the right atrium and ascending aorta. The heart is stopped and the valve is replaced.

Intervention Under Study: Minimally Invasive Ministernotomy:

The new technique of manubrium-limited ministernotomy, divides only the top quarter of the sternum from the sternal notch to 1cm below the manubrio-sternal junction; this enables access to perform the AVR. Potential benefits may include reductions in bleeding, post-operative pain, inflammatory response, hospital stay, and time away from work. The cardiothoracic surgical community are enthusiastic about the procedure; however they are clear that definitive benefit needs to be demonstrated in a randomised controlled trial before widespread adoption of the technique.

Inflammatory Markers

In minimally invasive cardiac surgical procedures, there is less tissue trauma and the right atrium is not directly cannulated; conversely the duration of cardiopulmonary bypass time and aortic cross clamp are longer. The mechanism for any observed benefits of the minimally invasive approach is unconfirmed, but may be due to a difference in systemic inflammatory response (SIR). SIR can be measured by
monitoring the profile of non-terminal pro-hormone brain natriuretic peptide (NT-proBNP) and cytokines in plasma. Brain natriuretic peptide (BNP) release is a marker of myocardial stress, myocardial damage and systemic inflammation (18).

This trial will determine if there is a difference in systemic inflammatory response to AVR via manubrium-limited ministernotomy when compared to conventional sternotomy by measuring inflammatory markers (NT-proBNP and cytokines) at pre and post-surgical time-points. We will seek to understand the mechanism underlying the observations we make. Our hypothesis is that patients who receive a sternotomy will bleed more and require more blood transfusions. The excess bleeding might be directly because of the increased surgical trauma or as a result of an increased systemic inflammatory response to sternotomy. A systematic inflammatory response may have wide-ranging post-operative effects and has previously been shown to increase atrial fibrillation, acute kidney injury, impair wound healing and reduce post-operative haemostasis (189).

**Trial Rationale**

Case series data at The JCUH suggest a potentially significant and clinically important difference in the need for red blood cell transfusion when comparing patients undergoing conventional and manubrium-limited surgery. Given the implications of transfusion for NHS resources and patient outcomes, and the potential benefits from this new technique, there is a need for a definitive trial. There has been one trial in the UK evaluating the 4th space median (minimally invasive) sternotomy (PB-PG-0408-16296; ISRCTN 58128724); this is now closed to recruitment and in follow-up. Thus far, no randomised trial has compared manubrium-limited to conventional AVR.
The need for AVR is increasing and, with an ageing population, the balance of surgical risk will become less favourable given the greater level of co-morbidity in older populations. Importantly, this new approach also has the potential to reduce the risk of post-operative lung injury, organ dysfunction, and immunosuppression, as well as reducing the burden on already overstretched blood transfusion services. A robust trial of the manubrium-limited technique compared with conventional surgery is imperative and timely to ensure that appropriate surgical strategies deliver improved patient outcomes and efficient use of scarce NHS resources.

The trial will run according to the principles of ICH GCP, and in accordance with relevant UK legislation and the Protocol.

Objectives
This trial will investigate whether new manubrium-limited surgery (intervention) reduces red blood cell transfusion rates compared to conventional cardiac surgery (control) for patients undergoing aortic valve replacement. The null hypothesis is that there will be no difference in the proportion of patients receiving red blood cell transfusion after manubrium limited ministernotomy when compared to conventional sternotomy for AVR rates between intervention and control groups.

Trial Design
A single centre, single-blind, randomised controlled superiority trial comparing patients undergoing aortic valve replacement (AVR) via manubrium-limited ministernotomy (intervention under study) or conventional median sternotomy (control arm/usual care); randomization will be performed using blocks with a 1:1 allocation.

Trial Setting
The study aims to recruit 270 patients in a single NHS Trust in the North of England.
Eligibility Criteria

Inclusion Criteria

Patients are eligible for the study if they:

1. are aged 18 years or over at the time of consent;
2. require first-time, non-emergency, isolated Aortic Valve Replacement surgery; and
3. are able and willing to provide written informed consent.

Exclusion Criteria

Patients are excluded from entering the study if they:

1. require concomitant cardiac procedure(s);
2. have a haemoglobin level < 90g/L;
3. are pregnant; have received previous cardiac surgery;
4. are unable to stop currently prescribed treatment affecting clotting;
5. have a haematological condition that would affect participation in the trial;
6. have infective endocarditis;
7. are prevented from having red blood cells and blood products according to a system of beliefs;
8. or have any other medical, psychiatric and or social reason that precludes participation.

Eligibility Check

Participants have their eligibility checked and confirmed within the 14 days prior to surgery. Eligibility is confirmed by one of the three operating cardiac surgeons who are clinical investigators for this trial.

Interventions

Manubrium-limited ministernotomy (intervention):

Manubrium-limited mini-ministernotomy (intervention arm) is performed using systemic normothermia. An incision is made from the sternal notch to the second intercostal...
space. The manubrium is divided longitudinally in the midline. The sternum is then transected in both directions from the second intercostal spaces until the midline incision is reached, creating a V-shape. This procedure is depicted in Figure 1. Aortic cannulation is through the ascending aorta. As the right atrium is poorly visualized with this technique, venous cannulation is percutaneous through the femoral vein (using a Seldinger technique guided by transoesophageal ECHO). Vacuum assist is used as necessary to aid venous drainage. Antegrade cardioplegia is used for myocardial protection and venting is via the pulmonary artery. A transverse aortotomy is performed, followed by standard aortic valve insertion using interrupted nonpledgeted braided sutures. The aortotomy is closed in a single or double layer. One pericardial drain and ventricular pacing wires are placed in all patients. Atrial wires are placed if needed. These steps are performed prior to removing the crossclamp to facilitate the view of the right atrium and ventricle. Sternal closure is with two wires in the manubrium and two wires from the body of the sternum up to the manubrium.

Insert Figure 1.

**Conventional Median Sternotomy (control):**

For the conventional technique, a standard median sternotomy is performed using systemic normothermia. Cannulation is via the ascending aorta with two-stage right atrial cannulation for venous drainage. Venting of the left ventricle is achieved via the pulmonary artery and myocardial protection is with cold blood antegrade cardioplegia. All valves are inserted using interrupted sutures.
During the trial, both operations are performed in accordance with an agreed and standardised anaesthetic protocol. Patients are given lorazepam as a premedication, followed by anaesthesia with propofol, fentanyl, rocuronium bromide and morphine. All patients are given a total dose of tranexamic acid (TXA) at 30mg/kg. Where patients have a pre-surgical creatinine >200 mmol/l, the dose of TXA is halved to 15mg/kg. Prior to cardiopulmonary bypass, systemic anticoagulation is achieved with heparin given at a dose that achieves an activated clotting time (ACT) of greater than 400 seconds. Fresh Frozen Plasma (FFP) is administered if the target ACT is not reached. During cardiopulmonary bypass, Hb is kept at 60g/L or above. Haemofiltration followed by red blood cell transfusion may be required to achieve this. Following CPB, protamine will be administered to reverse heparin, according to the dose of heparin given. Blood products may be used intraoperatively in the presence of excessive blood loss. Red blood cell salvage will be used in all patients.

All patients have the new aortic valve assessed at the end of surgery using a transoesophageal echocardiogram (TOE). Details of this, as well as any additional surgical intervention, including conversion to conventional sternotomy from manubrium-limited sternotomy, and any further TOE are recorded.

**Post-operative warfarin and aspirin administration**

Post-operatively, all patients having a biological prosthesis begin 75mg aspirin on the morning of the day following surgery. All patients having a mechanical prosthesis commence on warfarin on the evening of the day following surgery.

**Post-operative assessments and procedures**

The post-operative period (and trial protocol in relation to red blood cell and other blood product transfusion) begins once the patient has been admitted to Cardiac
Intensive Care Unit (CICU). Residual blood after cardiopulmonary bypass that has been bagged may all be given as a transfusion intravenously; the transfusion of this residual blood is commenced prior to CICU admission.

Blood and blood product usage following surgery

The post-operative red blood cell transfusion and blood product transfusion processes for this trial begin from the point of admission to the Cardiac Intensive Care Unit (CICU). All residual blood from the CPB reservoir and cell salvaged blood is returned to the patient; the following transfusion processes are implemented following complete transfusion of this blood, and continue until a patient is discharged following their index operation.

Trial patients receive a red blood cell transfusion if at least one of the following criteria are met:

- their Hb is <80 g/L
- a diagnosis of post-operative bleeding is made as defined by ≥400ml/h blood loss or ≥100ml/h for ≥ 4 hours with Hb ≥80g/L.
- blood loss leading to haemodynamic instability occurs irrespective of thromboelastography (TEG) and clotting profile results.

Trial patients receive a blood product transfusion if both of the following criteria are met:

- a diagnosis of post-operative bleeding occurs as defined by ≥400ml/h blood loss or ≥100ml/h for ≥ 4 hours.
- TEG or coagulation guided transfusion is indicated

Clinicians are able to transfuse, or decide not to transfuse, in violation of the protocol parameters; their reason for doing so is recorded.

Outcomes
Primary Outcome

The primary outcome of the trial is the proportion of patients who receive a red blood cell transfusion post-operatively and within 7 days of AVR surgery.

Secondary Outcomes

Secondary outcomes for this trial are:

- the proportion of patients who receive a red blood cell transfusion and during the intra-operative period, and the entire postoperative hospital stay.
- the mean number of red blood cell units transfused during the intra-operative period, post-operative period (from arrival at CICU to within the 7 days following AVR surgery) and the entire postoperative hospital stay.
- the proportion of patients receiving platelet transfusion or receiving fresh frozen plasma transfusion during the intra-operative period, within the 7 days following AVR surgery and during the entire hospital stay.
- the mean number of platelet transfusions or fresh frozen plasma transfusion units transfused received during the intra-operative period, within the 7 days following AVR surgery and during the entire hospital stay,
- mean postoperative blood loss (mls) measured from chest drains at 6 and 12 hours, and at the time of drain removal, following AVR surgery,
- operative success as defined by transthoracic echocardiographic assessment of left ventricular function, and degree of aortic regurgitation, within 6 weeks of AVR surgery,
- mean post-operative changes in haemoglobin (Hb) within the index hospital stay,
- mean post-operative changes in inflammatory markers on admission to CICU and on day 1 following AVR surgery,
- proportion of patients reporting moderate or severe post-operative sternal wound pain, measured daily using an 11 point numerical rating scale.
developed by the trial team, until patient is fit for hospital discharge, and at 6 and 12 weeks following AVR surgery.

- **rates of re-operation following index AVR surgery until 12 weeks**
- **rate of conversion to conventional AVR during index surgery.**
- **changes in forced expiratory volume and forced vital capacity on days 3 and 4 and at 6 weeks pulmonary function tests (PFTs) following AVR surgery,**
- **EuroQOL EQ-5D-3L (2019) scores, captured at baseline and on day 2, and 6 weeks and 12 weeks following AVR surgery, will be converted to health status scores using the value set (time trade off) (210) and provide patient-level QALY estimates as a health outcome (221). The EQ-5D-3L is a validated, self-reported outcome measure consisting of five dimensions: mobility, self-care, usual activity, pain / discomfort, anxiety / depression. Each dimension has three levels of response.**
- **mean time at which patients are fit for discharge from hospital following AVR surgery,**
- **health care utilisation during hospital stay and following discharge to 12 weeks from medical note review, GP records and patient reports,**
- **cost and cost effectiveness analyses estimated from QALY estimates and health care utilisation valued using national reference costs to 12 weeks,**
- **rates of related adverse events during the 12 weeks following surgery profiles including severity.**

**Participant Timeline**

Patients are followed for 12 weeks with follow up at 6 weeks and 12 weeks after discharge from hospital following their index AVR operation. **Figure 2 provides a flow chart of the patient pathway in the trial.**
Sample size calculation

This trial will determine if manubrium-limited ministernotomy is an appropriate clinical alternative to the existing operation (conventional sternotomy) in terms of red blood cell transfusion requirements in the seven days following index surgery. Currently, there is clinical and policy equipoise with no intention to extend the use of the new procedure until high quality RCT evidence is available.

Using Fisher’s Exact test, 90% power, 5% alpha, 270 patients are required to detect a 17% reduction in the proportion of patients requiring RBC transfusion (13% compared with 30%), using a two-sided test. Recruitment will continue until the target sample size is reached and 270 patients are contributing to the primary outcome.

Recruitment

Patients undergoing isolated AVR surgery will be identified at the point of referral or from the inpatient waiting list by the clinical team, and approached by a member of the research team about participation in MAVRIC. Patients will be consented by a Consultant Cardiothoracic Surgeon or a Surgical Registrar.

Allocation

Following consent, eligible patients are randomised to receive AVR by manubrium-limited ministernotomy or by conventional sternotomy following confirmation of eligibility. Randomisation is made using a permuted block randomisation, stratified by logistic EuroSCORE (low risk 0-3.50%, moderate risk 3.51-7.5% and high risk >7.5%) and by pre-operative Hb (90-125 g/L, 126–140 g/L, >140 g/L). A web-based randomisation system, managed by Durham Clinical Trials Unit ensures concealment of allocation.

Blinding
This is a single blind trial. Patients are not informed of the type of sternotomy they are planned to receive, or do receive, until completion of the pain assessment on day 2 following their operation. To enable blinding post-operatively, all patients have a trial specific opaque dressing applied to their sternal wound, and to their groin.

**Measures Taken to Avoid Bias**

This trial incorporates a number of methods to avoid bias.

- Concealment of allocation will be achieved through a web-based randomisation system, described above, managed by Durham Clinical Trials Unit. Named clinical research team members enter a minimum data set per patient before individual allocation to treatment is provided.

- Three consultant cardiothoracic surgeons perform all operations as part of this trial. Each is expert in both techniques and does not delegate to other trainee or consultant surgeons.

- Criteria for blood and blood product transfusions are detailed in the protocol and followed for all patients. Clinical staff in all cardiothoracic wards follow this protocol. Where clinical need requires blood to be given outside of the protocol, this is documented and described. The trigger for all transfusions is recorded.

- Patients are blind to the sternotomy procedure, both planned and received, for two days following their index surgery. All have opaque dressing applied to both the sternum and the groin to facilitate blinding; these are only removed, and the patient informed, following their day two trial assessments unless clinical need requires earlier removal. Sternal wound pain is assessed using an eleven point numerical rating scale, with all analgesic medication taken in the preceding four hours recorded.

- Fitness for discharge is measured using defined physiotherapy and clinical criteria; these are assessed daily from day three by a research team physiotherapist and by the surgical research team. The date that both physiotherapy and clinical
criteria are met is defined as the date the patient is fit for discharge. The date of actual discharge is also recorded.

- Where patients choose to withdraw from the study prior to seven days following their index surgery, permission is sought to continue data collection to support analysis of the primary endpoint.

**Data collection methods**

**Baseline Assessments**

In addition to usual care procedures, baseline assessments take place following consent and prior to surgery.

**Cardiovascular and significant current and past medical history**

A full medical history is recorded for each patient at baseline and includes details of all clinically significant past medical conditions and all clinically significant on-going medical conditions including full cardiovascular history.

**Physical assessment**

A physical assessment of height (measured in cm), and weight (measured in kg) determines Body Mass Index.

**Current medications**

A full list of the generic names of relevant medications taken by the patient is recorded within 14 days before surgery. The information includes frequency and dose. Changes or additions are recorded from baseline until the 12-week follow up visit.

For patients in both trial arms, pre-operative antiplatelet drugs (including clopidogrel and aspirin), and anti-coagulants (including heparin and warfarin) are discontinued 5
days prior to surgery. The exception is aspirin, which is stopped 5 days prior to surgery
where possible, however, continuation until the day of surgery does not exclude a
patient from the trial, and is recorded. These drugs may be re-started following
surgery at the discretion of the clinical team. Dates for re-starting medications are
recorded.

INR checks for warfarin patients
Patients on warfarin have their INR checked as part of routine care on admission to
hospital for their index surgery. Where an INR is ≤1.5, the patient proceeds to surgery.
Where a patient's INR is >1.5, appropriate treatment may be given and surgery may
need to be delayed. The INR for patients taking warfarin must be ≤1.5 prior to surgery.

Demographic information
The following demographic data is recorded:
- age
- gender
- ethnicity

Blood Tests
Blood tests are taken within 14 days prior to surgery and prior to randomisation:
- U&Es (Sodium, Potassium, Creatinine, Urea),
- Pregnancy test,
- Full Blood Count (Haemoglobin, Haematocrit, Platelets, White Cell Count),
- Coagulation screen (PT, PTR APTT, APTTR),
- Inflammatory markers (NT-proBNP, and cytokines).

Out of normal range blood parameters are assessed by the clinical team to confirm
that there are no clinically significant findings that would affect continuation in the
trial. The value of haemoglobin taken up to 14 days pre-surgery is used as a stratifying variable for randomisation.

Patients also have blood samples (stored as plasma) taken pre-operatively, on admission to CICU and 24 hours post-operatively. These are analysed to explore the following null hypotheses:

1. That there will be no difference between peri-operative inflammatory markers (IL-1, IL-6, IL-8, TNF-α IL-10) and markers of endothelial inflammation (VCAM-1, ICAM-1 or CD62E) between those undergoing AVR via manubrium-limited ministernotomy when compared to AVR via conventional sternotomy.

2. That there is no correlation between the number and proportion of patients who receive a red blood cell transfusion and the number of units transfused and peri-operative inflammatory markers (IL-1, IL-6, IL-8, IL-10 TNF-α).

**Echocardiogram**

Results from the latest echocardiogram (echo) pre-surgery are recorded. If an echo has not been done within 39 weeks (9 months) of consent, this is repeated at baseline.

**Pulmonary Function Tests**

Pulmonary Function tests of Forced Expiratory Volume (FEV1) and Forced Vital Capacity (FVC) are performed at baseline with patients sitting for both assessments. These assessments are repeated on days 3 and 4, and at 6 weeks following discharge from hospital after their index surgery.

**EuroSCORE**

Logistic EuroSCORE (2241) is determined prior to randomisation to be used as a stratifying variable, with the score recorded. The elements that determined the
logistic EuroSCORE pre-operatively are also recorded. EuroSCORE II (2342) and the elements that determine this score are also recorded.

Quality of Life Assessment (EuroQoL EQ-5D-3L (20))

Each patient completes the Euro-QoL EQ-5D-3L (2019) questionnaires at baseline. If the patient is physically unable to complete the questionnaires, or the assessment is being performed over the telephone, the research team administer them to the patient, who dictates their answers. The details of who is recording the patient’s responses are noted. Questionnaires are repeated at day 2, 6 weeks and 12 weeks (3 months) following discharge from hospital.

Assessment of Pain

Pain is assessed within 14 days prior to index surgery using an eleven point numerical rating scale. Pain is also assessed post-operatively (daily from post-operative day 2 until the patient is deemed ‘fit for discharge’, and at follow-up (6 and 12 weeks following discharge).

Retention of participants

Patients who withdraw have all data collected up until the point of withdrawal included in the study except where withdrawal is due to a related adverse event (AE) in which case the patient is followed until a stable outcome is achieved.

Data management

The study is managed by the Chief Investigator with support from Durham Clinical Trials Unit (DCTU).

Study data is recorded in each patient’s medical notes before being entered on to electronic Case Report Forms (e-CRFs). Data entered into the e-CRF must be consistent with the information in the medical notes. Discrepancies are noted and
explained. Un-anonymised data is held on site in accordance with local Trust policies. Patients are identified by a unique study number at enrolment. All data passed to DCTU has patient identifiers removed, except date of birth, gender, ethnicity and unique study ID. All data are handled in a confidential manner by DCTU, the research team and by members of the DMC and TSC.

**Statistical methods**

The null hypothesis is that there will be no difference in the proportion of patients receiving red blood cell transfusion after manubrium-limited ministernotomy when compared to conventional sternotomy for AVR.

This trial will determine if manubrium-limited ministernotomy is an appropriate clinical alternative to the existing operation (conventional sternotomy) in terms of red blood cell transfusion requirements in the seven days following index surgery. Analysis of the primary endpoint will be conducted using Fisher’s exact test. Sensitivity analysis will also be performed for the primary endpoint using a logistic regression model to account for potential confounders and stratification factors. Continuous outcomes will be analysed using general linear models. Correlation between repeated measures per patient will be appropriately accounted for in the linear models where applicable. Binary data will be analysed using logistic regression where there are no repeated data per patient. Repeated binary data will be analysed using generalised estimating equations. Stratification factors and chance baseline imbalances following randomisation will be explored for the primary and secondary outcomes.

Analysis will follow intention to treat principles with patients analysed according to the surgery allocated by randomisation and irrespective of surgery received, subsequent management or events. Every effort will be made to retain and include all patients who receive surgery as part of the trial.
A prospective economic evaluation is integrated into the trial design and applies an NHS perspective to the inclusion of costs. Mechanisms of missingness within the data will be explored and multiple imputation methods will be applied to impute missing data and minimise bias. Imputation sets will be used in bivariate analysis of costs and QALYS to generate incremental cost per QALY estimates and credible intervals (24-27). It is anticipated that incremental costs and benefits will be captured within the trial, although extrapolated economic modelling will be considered if appropriate. Findings will be presented on the ICER plane and using Cost-Effectiveness Acceptability Curves (CEACs). Economic analysis will use within trial (stochastic) and, if appropriate, extrapolated (probabilistic) models. Patient level cost data will be estimated by applying national reference costs to reported healthcare resource use. Stochastic incremental cost-effectiveness analysis will be used to estimate the value of manubrium-limited ministernotomy in place of conventional sternotomy for AVR, using the cost-QALY metric, by generating a bootstrapped Incremental Cost Effectiveness Ratio (ICER) plane and Cost-Effectiveness Acceptability Curve (CEAC).

**Monitoring Governance**

The trial is overseen by a Trial Steering Committee, which includes an independent chair and two other independent members (one of whom is a patient). In addition the trial has a DMC, which meets 6 monthly, and oversees all ethical and safety issues in accordance with a study specific DAMOCLES charter (28-33) for data monitoring committees. All members are independent of the study team, although the Trial Manager, Chief Investigator and some other members of the Trial Management Group (TMG) attend the open sessions in order to inform the DMC of trial progress.

**Harms Reporting of adverse events**
Adverse Events (AEs) and Serious Adverse Events (SAEs) are recorded and reported from the time of index surgery until completion or withdrawal. SAEs are reported within 24 hours of the research team becoming aware of the event to the Sponsor. Where required, these events undergo expedited reporting to the Research Ethics Committee. All AEs are assessed for severity, causality, expectedness and seriousness by an Investigator; all are reviewed by the DMC.

**Research eEthics Approval**

This protocol and all trial related documents were originally approved by the National Research Ethics Service Committee, North East - Newcastle & North Tyneside 1, in March 2014 [IRAS Project 137295; REC Reference 14/NE/0005]. Since initial approval, three amendments have been made and approved; thus this is version 4.5 of the protocol.

**Declaration of interests**

No members of the research team, nor any collaborators, have any conflicts of interest relating to this trial.

**Dissemination**

On-going patient and public involvement informs appropriate methods of dissemination to patients. Feedback will be given to national surgical leads via the Society for Cardiothoracic Surgeons in Great Britain and Ireland, maximising the exposure of findings to cardiac surgeons diagnosing and treating patients requiring AVR.

Findings will be presented at national specialist meetings to raise awareness. We will engage directly with surgeons and cardiothoracic units around the country sharing results. Data will be presented at the annual meeting of the Society for
Cardiothoracic Surgeons in Great Britain and Ireland and we anticipate this to be the main forum for disseminating findings from this study.

Discussion

This is the first trial to examine aortic valve replacement via manubrium-limited ministernotomy versus conventional sternotomy when comparing red blood cell transfusion rates following surgery. MAVRIC will determine if manubrium-limited ministernotomy should be adopted as best practice for patients requiring AVR surgery.

It was not possible to blind clinicians to the surgical procedure provided, although transfusion decisions are protocol-driven and should not be procedure-related. The inclusion of patient blinding was in response to a funding panel recommendation: it has been possible to implement this through the use of opaque dressing and means that patient-reported pain scores at two days will be blinded. We will assess the effectiveness of blinding by inviting patients to indicate which treatment they think they have received before removing the dressing.

Surgical trials present significant challenges; strengths of this trial include a rigorous research design, standardised surgery performed by experienced consultant cardiothoracic surgeons, an agreed anaesthetic regimen, patient blinding, and consultant-led patient recruitment. Each discipline within the Cardiothoracic Division at JCUH is supporting and collaborating with the Chief Investigator. MAVRIC will demonstrate that complex surgical trials can be delivered to exemplary standards and provide the community with the knowledge required to inform future care for patients requiring aortic valve replacement surgery.

Protocol Version.

Version 45
Trial status

The trial began recruiting in March 2014; the trial is due to report in 2017.

List of abbreviations

AVR – Aortic Valve Replacement
JCUH – The James Cook University Hospital
CICU – Cardiac Intensive Care Unit
TEG – Thromboelastography

Roles and Responsibilities

Contributorship - Authors’ contributions

EA conceived ideas for the study. All authors contributed to the design and writing of the full MAVRIC protocol. EA, HH, and RHM wrote the first draft of this paper; all authors commented and amended drafts of the paper and approved the final version. All authors read and approved the final manuscript.

Sponsor and Funder

The trial is being sponsored by South Tees Hospitals NHS Foundation Trust and is run in collaboration with Durham Clinical Trials Unit at Durham University. It is funded by the National Institute for Health Research (NIHR) Research for Patient Benefit Programme (PB-PG-1112-29035). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Further research nurse and NHS staff support is provided through the NIHR Clinical Research Network (2964).

Acknowledgements.
This trial would not be possible without the enthusiasm and commitment of clinicians, nurses, professionals and patients within the Cardiothoracic Division and Research and Development Department at The James Cook University Hospital and the wider cardiothoracic surgical community.

References


9. Vasques F, Lucenteforte E, Paone R, Mugelli A, Biancari F. Outcome of patients aged ≥80 years undergoing combined aortic valve replacement and coronary artery


Figure 1.

No permission for this is required; it was developed by Mr Enoch Akowuah.
Patient identified at point of referral or from inpatient waiting list and seen by consultant cardiac surgeon

Written consent obtained and baseline assessments

Surgeon confirms patient’s eligibility

Randomisation

Patient randomised to receive AVR via manubrium-limited ministernotomy

Patient randomised to receive AVR via conventional median sternotomy

AVR surgery received

Admission to CICU. Begin MAVRIC blood and blood product transfusion protocol. Take FBC, Coag and inflammatory marker blood

Post-Op Day 1. FBC, Coag and inflammatory marker bloods. Assess fitness for transfer

Post-Op Day 2. FBC, complete EQ-5D-3L, EQ-VAS questionnaires and pain score. Ask patient about allocation prior to un-blinding.

Post-Op Day 3 FBC, PFTs (FEV1 and FVC), pain score. Assess fitness for discharge (daily until applicable).

Post-Op Day 4 FBC, PFTs (FEV1 and FVC), pain score.

Post-Op Day 5 daily until fit for discharge FBC, pain score

6 week follow up visit ECHO, PFTs, EQ-5D-3L, EQ-VAS & pain score

12 week follow up (via telephone) EQ-5D-3L, EQ-VAS and pain score

Figure 2

Click here to download Figure MAVRIC_Figure2.pdf
Click here to access/download
Supplementary Material
MAVRIC_SPIRIT_checklist.doc